These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2004-005001-29||Efficacy and safety of ozarelix acetate, a new GnRH antagonist in male patients with mild to moderate Alzheimer’s Disease (Regimen: 130 mg q4w, x3)||2007-12-17||due-trials|
|Listed as ongoing, but also has a completion date||2007-002598-30||Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind placebo-controlled efficacy study||2009-12-16||bad-data|
|Completed, but no date||2007-002663-26||Antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin, in women with LHRH receptor positive gynecological tumors||bad-data|
|Not reported||2007-003414-34||Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1year placebo-controlled efficacy study and long-term safety assessment||2009-12-16||due-trials|
|Completed, but no date||2007-004865-17||Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study||bad-data|
|Not reported||2010-018893-19||A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib||2013-03-11||due-trials|
|Not reported||2012-000134-19||A randomised, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer||2014-06-10||due-trials|
|Reported results||2012-005546-38||Randomised controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer||2017-03-02||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2015-002337-22||Confirmatory validation of oral macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the diagnosis of Adult Growth Hormone Deficiency (AGHD) in comparison with the Insulin Tolerance Test (IT...||2016-12-29||bad-data|
|Ongoing||2018-001988-23||Open label, group comparison, dose escalation trial to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of macimorelin acetate after single oral dosing of 0.25 mg/kg, 0.5 mg/kg,...||not-yet-due|